Current, experimental, and future treatments in inflammatory bowel disease: a clinical review

References

• Baumgart DC, Sandborn WJ. Crohn's disease. Lancet. 2012;380:1590–1605.
   PubMed Web of Science ®Google Scholar
• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389:1756–1770.
   PubMed Web of Science ®Google Scholar
• Park JH, Peyrin-Biroulet L, Eisenhut M, et al. IBD immunopathogenesis: a comprehensive review of inflammatory molecules. Autoimmun Rev. 2017;16:416–426.
   PubMed Web of Science ®Google Scholar
• de Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13:13–27.
   PubMed Web of Science ®Google Scholar
• Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54.e42. quiz e30.
   PubMed Web of Science ®Google Scholar
• Duchmann R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol. 1995;102:448–455.
   PubMed Web of Science ®Google Scholar
• Ott SJ, Schreiber S. Reduced microbial diversity in inflammatory bowel diseases. Gut. 2006;55:1207.
   PubMed Web of Science ®Google Scholar
• Lepage P, Hasler R, Spehlmann ME, et al. Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. Gastroenterology. 2011;141:227–236.
   PubMed Web of Science ®Google Scholar
• Prosberg M, Bendtsen F, Vind I, et al. The association between the gut microbiota and the inflammatory bowel disease activity: a systematic review and meta-analysis. Scand J Gastroenterol. 2016;51:1407–1415.
   PubMed Web of Science ®Google Scholar
• Seksik P, Rigottier GL, Gramet G, et al. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut. 2003;52:237–242.
   PubMed Web of Science ®Google Scholar
• Willing BP, Dicksved J, Halfvarson J, et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology. 2010;139:1844–1854.e1841.
   PubMed Web of Science ®Google Scholar
• Sokol H, Seksik P, Furet JP, et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis. 2009;15:1183–1189.
   PubMed Web of Science ®Google Scholar
• Joossens M, Huys G, Cnockaert M, et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut. 2011;60:631–637.
   PubMed Web of Science ®Google Scholar
• Wang W, Chen L, Zhou R, et al. Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. J Clin Microbiol. 2014;52:398–406.
   PubMed Web of Science ®Google Scholar
• Bevins CL, Stange EF, Wehkamp J. Decreased Paneth cell defensin expression in ileal Crohn's disease is independent of inflammation, but linked to the NOD2 1007fs genotype. Gut. 2009;58:882–883. discussion 883–884.
   PubMed Web of Science ®Google Scholar
• Ostaff MJ, Stange EF, Wehkamp J. Antimicrobial peptides and gut microbiota in homeostasis and pathology. EMBO Mol Med. 2013;5:1465–1483.
   PubMed Web of Science ®Google Scholar
• Ni J, Wu GD, Albenberg L, et al. Gut microbiota and IBD: causation or correlation? Nat Rev Gastroenterol Hepatol. 2017;14:573–584.
   PubMed Web of Science ®Google Scholar
• Zeng MY, Inohara N, Nunez G. Mechanisms of inflammation-driven bacterial dysbiosis in the gut. Mucosal Immunol. 2017;10:18–26.
   PubMed Web of Science ®Google Scholar
• Wallace KL, Zheng LB, Kanazawa Y, et al. Immunopathology of inflammatory bowel disease. World J Gastroenterol. 2014;20:6–21.
   PubMed Web of Science ®Google Scholar
• Choy MC, Visvanathan K, De Cruz P. An overview of the innate and adaptive immune system in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23:2–13.
   PubMed Web of Science ®Google Scholar
• Zeissig S, Burgel N, Gunzel D, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut. 2007;56:61–72.
   PubMed Web of Science ®Google Scholar
• Salim SY, Soderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:362–381.
   PubMed Web of Science ®Google Scholar
• Flannigan KL, Geem D, Harusato A, et al. Intestinal antigen-presenting cells: key regulators of immune homeostasis and inflammation. Am J Pathol. 2015;185:1809–1819.
   PubMed Web of Science ®Google Scholar
• Davies JM, Abreu MT. The innate immune system and inflammatory bowel disease. Scand J Gastroenterol. 2015;50:24–33.
   PubMed Web of Science ®Google Scholar
• Niess JH, Brand S, Gu X, et al. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science. 2005;307:254–258.
   PubMed Web of Science ®Google Scholar
• Szebeni B, Veres G, Dezsofi A, et al. Increased expression of Toll-like receptor (TLR) 2 and TLR4 in the colonic mucosa of children with inflammatory bowel disease. Clin Exp Immunol. 2008;151:34–41.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Thomas S, Przesdzing I, et al. Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel disease. Clin Exp Immunol. 2009;157:423–436.
   PubMed Web of Science ®Google Scholar
• Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411:599–603.
   PubMed Web of Science ®Google Scholar
• Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411:603–606.
   PubMed Web of Science ®Google Scholar
• Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361:2066–2078.
   PubMed Web of Science ®Google Scholar
• Zundler S, Neurath MF. Immunopathogenesis of inflammatory bowel diseases: functional role of T cells and T cell homing. Clin Exp Rheumatol. 2015;33:S19–S28.
   PubMed Web of Science ®Google Scholar
• Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. JCO. 2006;24:2283–2289.
   PubMed Web of Science ®Google Scholar
• Spehlmann ME, Begun AZ, Burghardt J, et al. Epidemiology of inflammatory bowel disease in a German twin cohort: results of a nationwide study. Inflamm Bowel Dis. 2008;14:968–976.
   PubMed Web of Science ®Google Scholar
• Bengtson MB, Solberg C, Aamodt G, et al. Familial aggregation in Crohn's disease and ulcerative colitis in a Norwegian population-based cohort followed for ten years. J Crohns Colitis. 2009;3:92–99.
   PubMed Web of Science ®Google Scholar
• Hampe J, Franke A, Rosenstiel P, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet. 2007;39:207–211.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Rosenstiel P, Albrecht M, et al. Genetics of Crohn disease, an archetypal inflammatory barrier disease. Nat Rev Genet. 2005;6:376–388.
   PubMed Web of Science ®Google Scholar
• Buisine MP, Desreumaux P, Debailleul V, et al. Abnormalities in mucin gene expression in Crohn's disease. Inflamm Bowel Dis. 1999;5:24–32.
   PubMed Web of Science ®Google Scholar
• Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet. 2010;42:1118–1125.
   PubMed Web of Science ®Google Scholar
• Orholm M, Munkholm P, Langholz E, et al. Familial occurrence of inflammatory bowel disease. N Engl J Med. 1991;324:84–88.
   PubMed Web of Science ®Google Scholar
• Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology. 2017;152:313–321.e312.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN. Environmental triggers for inflammatory bowel disease. Curr Gastroenterol Rep. 2013;15:302.
   PubMedGoogle Scholar
• Gent AE, Hellier MD, Grace RH, et al. Inflammatory bowel disease and domestic hygiene in infancy. Lancet. 1994;343:766–767.
   PubMed Web of Science ®Google Scholar
• Aamodt G, Bukholm G, Jahnsen J, et al. The association between water supply and inflammatory bowel disease based on a 1990–1993 cohort study in southeastern Norway. Am J Epidemiol. 2008;168:1065–1072.
   PubMed Web of Science ®Google Scholar
• Porter CK, Tribble DR, Aliaga PA, et al. Infectious gastroenteritis and risk of developing inflammatory bowel disease. Gastroenterology. 2008;135:781–786.
   PubMed Web of Science ®Google Scholar
• Parkes GC, Whelan K, Lindsay JO. Smoking in inflammatory bowel disease: impact on disease course and insights into the aetiology of its effect. J Crohns Colitis. 2014;8:717–725.
   PubMed Web of Science ®Google Scholar
• Caprilli R, Cesarini M, Angelucci E, et al. The long journey of salicylates in ulcerative colitis: the past and the future. J Crohns Colitis. 2009;3:149–156.
   PubMed Web of Science ®Google Scholar
• Hindryckx P, Baert F, Hart A, et al. Clinical trials in ulcerative colitis: a historical perspective. ECCOJC. 2015;9:580–588.
   Google Scholar
• Machella TE, Hollan OR. The effect of cortisone on the clinical course of chronic regional enteritis and chronic idiopathic ulcerative colitis. Am J Med Sci. 1951;221:501–507.
   PubMed Web of Science ®Google Scholar
• Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J. 1954;2:375–378.
   PubMed Web of Science ®Google Scholar
• Dubois-Camacho K, Ottum PA, Franco-Munoz D, et al. Glucocorticosteroid therapy in inflammatory bowel diseases: from clinical practice to molecular biology. World J Gastroenterol. 2017;23:6628–6638.
   PubMed Web of Science ®Google Scholar
• Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:590–599. quiz 600.
   PubMed Web of Science ®Google Scholar
• Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11:769–784.
   PubMed Web of Science ®Google Scholar
• Hauso O, Martinsen TC, Waldum H. 5-Aminosalicylic acid, a specific drug for ulcerative colitis. Scand J Gastroenterol. 2015;50:933–941.
   PubMed Web of Science ®Google Scholar
• Gomollon F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 1: diagnosis and medical management. ECCOJC. 2017;11:3–25.
   Web of Science ®Google Scholar
• Brooke BN, Hoffmann DC, Swarbrick ET. Azathioprine for Crohn's disease. Lancet. 1969;2:612–614.
   PubMed Web of Science ®Google Scholar
• Mantzaris GJ. Thiopurines and methotrexate use in IBD patients in a biologic era. Curr Treat Options Gastroenterol. 2017;15:84–104.
   PubMedGoogle Scholar
• Carbonnel F, Colombel JF, Filippi J, et al. Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis. Gastroenterology. 2016;150:380–388.e384.
   PubMed Web of Science ®Google Scholar
• Denmark VK, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update. Expert Rev Clin Immunol. 2013;9:77–92.
   PubMed Web of Science ®Google Scholar
• Mulder DJ, Noble AJ, Justinich CJ, et al. A tale of two diseases: the history of inflammatory bowel disease. J Crohns Colitis. 2014;8:341–348.
   PubMedGoogle Scholar
• Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet. 1997;349:521–524.
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029–1035.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52–65.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323–333. quiz 591.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60:780–787.
   PubMed Web of Science ®Google Scholar
• Desreumaux P, Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid – new evidence. Aliment Pharmacol Ther. 2006;24 Suppl.1:2–9.
   PubMed Web of Science ®Google Scholar
• Pedersen G. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium. Dan Med J. 2015;62:B4973.
   PubMed Web of Science ®Google Scholar
• Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med. 2005;201:1205–1215.
   PubMed Web of Science ®Google Scholar
• Torres J, Danese S, Colombel JF. New therapeutic avenues in ulcerative colitis: thinking out of the box. Gut. 2013;62:1642–1652.
   PubMed Web of Science ®Google Scholar
• Curkovic I, Egbring M, Kullak-Ublick GA. Risks of inflammatory bowel disease treatment with glucocorticosteroids and aminosalicylates. Dig Dis. 2013;31:368–373.
   PubMed Web of Science ®Google Scholar
• Troncone E, Monteleone G. The safety of non-biological treatments in ulcerative colitis. Expert Opin Drug Saf. 2017;16:779–789.
   PubMed Web of Science ®Google Scholar
• Brown G. 5-Aminosalicylic acid-associated myocarditis and pericarditis: a narrative review. CJHP. 2016;69:466–472.
   Google Scholar
• Oppong E, Cato AC. Effects of glucocorticoids in the immune system. Adv Exp Med Biol. 2015;872:217–233.
   PubMed Web of Science ®Google Scholar
• Ratman D, Vanden Berghe W, Dejager L, et al. How glucocorticoid receptors modulate the activity of other transcription factors: a scope beyond tethering. Mol Cell Endocrinol. 2013;380:41–54.
   PubMed Web of Science ®Google Scholar
• Gabryel M, Skrzypczak-Zielinska M, Kucharski MA, et al. The impact of genetic factors on response to glucocorticoids therapy in IBD. Scand J Gastroenterol. 2016;51:654–665.
   PubMed Web of Science ®Google Scholar
• Bonovas S, Nikolopoulos GK, Lytras T, et al. Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: systematic review and network meta-analysis. Br J Clin Pharmacol. 2018;84:239–251.
   PubMed Web of Science ®Google Scholar
• Moon W, Loftus EV, Jr. Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2016;43:863–883.
   PubMed Web of Science ®Google Scholar
• Teml A, Schaeffeler E, Herrlinger KR, et al. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet. 2007;46:187–208.
   PubMed Web of Science ®Google Scholar
• Thomas CW, Myhre GM, Tschumper R, et al. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J Pharmacol Exp Ther. 2005;312:537–545.
   PubMed Web of Science ®Google Scholar
• Chang S, Hanauer S. Optimizing pharmacologic management of inflammatory bowel disease. Expert Rev Clin Pharmacol. 2017;10:595–607.
   PubMed Web of Science ®Google Scholar
• Cohn HM, Dave M, Loftus EV. Jr. Understanding the cautions and contraindications of immunomodulator and biologic therapies for use in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23:1301–1315.
   PubMed Web of Science ®Google Scholar
• Brown PM, Pratt AG, Isaacs JD. Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol. 2016;12:731–742.
   PubMed Web of Science ®Google Scholar
• van Dieren JM, Kuipers EJ, Samsom JN, et al. Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of IBD. Inflamm Bowel Dis. 2006;12:311–327.
   PubMed Web of Science ®Google Scholar
• Egan LJ, Sandborn WJ, Mays DC, et al. Plasma and rectal adenosine in inflammatory bowel disease: effect of methotrexate. Inflamm Bowel Dis. 1999;5:167–173.
   PubMed Web of Science ®Google Scholar
• Majumdar S, Aggarwal BB. Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation. J Immunol. 2001;167:2911–2920.
   PubMed Web of Science ®Google Scholar
• Cesarini M, Festa S, Papi C. Methotrexate in Crohn's disease: a new face for an old drug? Expert Rev Gastroenterol Hepatol. 2016;10:1135–1144.
   PubMed Web of Science ®Google Scholar
• Gabbani T, Deiana S, Lunardi S, et al. Safety profile of methotrexate in inflammatory bowel disease. Expert Opin Drug Saf. 2016;15:1427–1437.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088–1094.
   PubMed Web of Science ®Google Scholar
• Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology. 2003;124:1774–1785.
   PubMed Web of Science ®Google Scholar
• ten Hove T, van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut. 2002;50:206–211.
   PubMed Web of Science ®Google Scholar
• Atreya R, Zimmer M, Bartsch B, et al. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14+ macrophages. Gastroenterology. 2011;141:2026–2038.
   PubMed Web of Science ®Google Scholar
• Mitoma H, Horiuchi T, Hatta N, et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology. 2005;128:376–392.
   PubMed Web of Science ®Google Scholar
• Boschetti G, Nancey S, Sardi F, et al. Therapy with anti-TNFalpha antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:160–170.
   PubMed Web of Science ®Google Scholar
• Di Sabatino A, Biancheri P, Piconese S, et al. Peripheral regulatory T cells and serum transforming growth factor-beta: relationship with clinical response to infliximab in Crohn's disease. Inflamm Bowel Dis. 2010;16:1891–1897.
   PubMed Web of Science ®Google Scholar
• Li Z, Arijs I, De Hertogh G, et al. Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab. Inflamm Bowel Dis. 2010;16: 1299–1310.
   PubMed Web of Science ®Google Scholar
• Dige A, Hvas CL, Deleuran B, et al. Adalimumab treatment in Crohn's disease does not induce early changes in regulatory T cells. Scand J Gastroenterol. 2011;46:1206–1214.
   PubMed Web of Science ®Google Scholar
• Hvas CL, Kelsen J, Agnholt J, et al. Discrete changes in circulating regulatory T cells during infliximab treatment of Crohn's disease. Autoimmunity. 2010;43:325–333.
   PubMed Web of Science ®Google Scholar
• Saruta M, Yu QT, Fleshner PR, et al. Characterization of FOXP3 + CD4+ regulatory T cells in Crohn's disease. Clin Immunol. 2007;125:281–290.
   PubMed Web of Science ®Google Scholar
• Liu C, Xia X, Wu W, et al. Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohn's disease. Clin Exp Immunol. 2013;173:102–111.
   PubMed Web of Science ®Google Scholar
• Yu L, Yang X, Xia L, et al. Infliximab preferentially induces clinical remission and mucosal healing in short course Crohn's disease with luminal lesions through balancing abnormal immune response in gut mucosa. Mediators Inflamm. 2015;2015:793764.
   PubMedGoogle Scholar
• Lugering A, Schmidt M, Lugering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology. 2001;121:1145–1157.
   PubMed Web of Science ®Google Scholar
• Dige A, Magnusson MK, Ohman L, et al. Reduced numbers of mucosal DR(int) macrophages and increased numbers of CD103(+) dendritic cells during anti-TNF-alpha treatment in patients with Crohn's disease. Scand J Gastroenterol. 2016;51:692–699.
   PubMed Web of Science ®Google Scholar
• Di Sabatino A, Pender SL, Jackson CL, et al. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology. 2007;133:137–149.
   PubMed Web of Science ®Google Scholar
• Arijs I, De Hertogh G, Machiels K, et al. Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment. Am J Gastroenterol. 2011;106:748–761.
   PubMed Web of Science ®Google Scholar
• Vos AC, Wildenberg ME, Arijs I, et al. Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro. Inflamm Bowel Dis. 2012;18:401–408.
   PubMed Web of Science ®Google Scholar
• Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol. 2008;103:944–948.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Enevold C, Ainsworth MA, et al. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease. Aliment Pharmacol Ther. 2012;36:650–659.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Bendtzen K, Brynskov J, et al. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial. Am J Gastroenterol. 2014;109:1055–1064.
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148:1320–1329.e1323.
   PubMed Web of Science ®Google Scholar
• Nyboe Andersen N, Pasternak B, Friis-Moller N, et al. Association between tumour necrosis factor-alpha inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study. BMJ. 2015;350:h2809.
   PubMed Web of Science ®Google Scholar
• Jess T, Horvath-Puho E, Fallingborg J, et al. Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study. Am J Gastroenterol. 2013;108:1869–1876.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016;375:1946–1960.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012;367:1519–1528.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, D'Haens G, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017;389:1699–1709.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med. 2003;348:24–32.
   PubMed Web of Science ®Google Scholar
• Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348:15–23.
   PubMed Web of Science ®Google Scholar
• Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005;353:362–368.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369:711–721.
   PubMed Web of Science ®Google Scholar
• Zundler S, Neurath MF. Novel Insights into the mechanisms of gut homing and antiadhesion therapies in inflammatory bowel diseases. Inflamm Bowel Dis. 2017;23:617–627.
   PubMed Web of Science ®Google Scholar
• Zundler S, Fischer A, Schillinger D, et al. The alpha4beta1 homing pathway is essential for ileal homing of Crohn's disease effector T cells in vivo. Inflamm Bowel Dis. 2017;23:379–391.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Su C, Panes J. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;377:496–497.
   PubMed Web of Science ®Google Scholar
• Panes J, Sandborn WJ, Schreiber S, et al. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017;66:1049–1059.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389:266–275.
   PubMed Web of Science ®Google Scholar
• Vetter M, Neurath MF. Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges. Ther Adv Gastroenterol. 2017;10:773–790.
   PubMed Web of Science ®Google Scholar
• Olivera P, Danese S, Peyrin-Biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut. 2017;66:199–209.
   PubMed Web of Science ®Google Scholar
• Boland BS, Sandborn WJ, Chang JT. Update on Janus kinase antagonists in inflammatory bowel disease. Gastroenterol Clin N Am. 2014;43:603–617.
   PubMed Web of Science ®Google Scholar
• Yoshimura N, Watanabe M, Motoya S, et al. Safety and efficacy of AJM300, an oral antagonist of alpha4 integrin, in induction therapy for patients with active ulcerative colitis. Gastroenterology. 2015;149:1775–1783.e1772.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Wolf DC, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med. 2016;374:1754–1762.
   PubMed Web of Science ®Google Scholar
• Boirivant M, Pallone F, Di Giacinto C, et al. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology. 2006;131:1786–1798.
   PubMed Web of Science ®Google Scholar
• Di Sabatino A, Jackson CL, Pickard KM, et al. Transforming growth factor beta signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures. Gut. 2009;58:777–789.
   PubMed Web of Science ®Google Scholar
• Monteleone G, Neurath MF, Ardizzone S, et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med. 2015;372:1104–1113.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sands BE, Rossiter G, et al. Effects of Mongersen (GED-0301) on endoscopic and clinical outcomes in patients with active Crohn's disease. Gastroenterology. 2018;154:61–64.e66.
   PubMed Web of Science ®Google Scholar
• Reich KM, Fedorak RN, Madsen K, et al. Vitamin D improves inflammatory bowel disease outcomes: basic science and clinical review. World J Gastroenterol. 2014;20:4934–4947.
   PubMed Web of Science ®Google Scholar
• Opstelten J, Chan S, Hart A, et al. Prediagnostic serum vitamin D levels and risk of inflammatory bowel disease: a pan-European, nested case-control study. Gastroenterology. 2017;152:S59.
   Web of Science ®Google Scholar
• Jorgensen SP, Hvas CL, Agnholt J, et al. Active Crohn's disease is associated with low vitamin D levels. J Crohns Colitis. 2013;7:e407–e413.
   PubMedGoogle Scholar
• Ham M, Longhi MS, Lahiff C, et al. Vitamin D levels in adults with Crohn's disease are responsive to disease activity and treatment. Inflamm Bowel Dis. 2014;20:856–860.
   PubMed Web of Science ®Google Scholar
• Sadeghian M, Saneei P, Siassi F, et al. Vitamin D status in relation to Crohn's disease: meta-analysis of observational studies. Nutrition. 2016;32:505–514.
   PubMed Web of Science ®Google Scholar
• Ulitsky A, Ananthakrishnan AN, Naik A, et al. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity. JPEN J Parenter Enteral Nutr. 2011;35:308–316.
   PubMed Web of Science ®Google Scholar
• Carlsen K, Jakobsen C, Kallemose T, et al. F-calprotectin and blood markers correlate to quality of life in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2017;65:539–545.
   PubMed Web of Science ®Google Scholar
• Kabbani TA, Koutroubakis IE, Schoen RE, et al. Association of vitamin D level with clinical status in inflammatory bowel disease: a 5-year longitudinal study. Am J Gastroenterol. 2016;111:712–719.
   PubMed Web of Science ®Google Scholar
• Zullow S, Jambaulikar G, Rustgi A, et al. Risk factors for vitamin D deficiency and impact of repletion in a tertiary care inflammatory bowel disease population. Dig Dis Sci. 2017;62:2072–2078.
   PubMed Web of Science ®Google Scholar
• Jorgensen SP, Agnholt J, Glerup H, et al. Clinical trial: vitamin D3 treatment in Crohn's disease – a randomised double-blind placebo-controlled study. Aliment Pharmacol Ther. 2010;32:377–383.
   PubMed Web of Science ®Google Scholar
• Frigstad SO, Hoivik M, Jahnsen J, et al. Vitamin D deficiency in inflammatory bowel disease: prevalence and predictors in a Norwegian outpatient population. Scand J Gastroenterol. 2017;52:100–106.
   PubMed Web of Science ®Google Scholar
• Raftery T, Martineau AR, Greiller CL, et al. Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn's disease: results from a randomised double-blind placebo-controlled study. United Eur Gastroenterol J. 2015;3:294–302.
   PubMed Web of Science ®Google Scholar
• Schaffler H, Schmidt M, Huth A, et al. Clinical factors are associated with vitamin D levels in IBD patients – a retrospective analysis. J Dig Dis. 2018;19:24–32.
   PubMed Web of Science ®Google Scholar
• Winter RW, Collins E, Cao B, et al. Higher 25-hydroxyvitamin D levels are associated with greater odds of remission with anti-tumour necrosis factor-alpha medications among patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;45:653–659.
   PubMed Web of Science ®Google Scholar
• Zator ZA, Cantu SM, Konijeti GG, et al. Pretreatment 25-hydroxyvitamin D levels and durability of anti-tumor necrosis factor-α therapy in inflammatory bowel diseases. JPEN J Parenter Enteral Nutr. 2014;38:385–391.
   PubMed Web of Science ®Google Scholar
• Palmer HG, Gonzalez-Sancho JM, Espada J, et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol. 2001;154:369–387.
   PubMed Web of Science ®Google Scholar
• Fujita H, Sugimoto K, Inatomi S, et al. Tight junction proteins claudin-2 and -12 are critical for vitamin D-dependent Ca2+ absorption between enterocytes. Mol Biol Cell. 2008;19:1912–1921.
   PubMed Web of Science ®Google Scholar
• Unger WW, Laban S, Kleijwegt FS, et al. Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur J Immunol. 2009;39:3147–3159.
   PubMed Web of Science ®Google Scholar
• Bartels LE, Jorgensen SP, Bendix M, et al. 25-Hydroxy vitamin D3 modulates dendritic cell phenotype and function in Crohn's disease. Inflammopharmacology. 2013;21:177–186.
   PubMed Web of Science ®Google Scholar
• Bartels LE, Bendix M, Hvas CL, et al. Oral vitamin D3 supplementation reduces monocyte-derived dendritic cell maturation and cytokine production in Crohn's disease patients. Inflammopharmacology. 2014;22:95–103.
   PubMed Web of Science ®Google Scholar
• Joshi S, Pantalena LC, Liu XK, et al. 1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol. 2011;31:3653–3669.
   PubMed Web of Science ®Google Scholar
• Nanduri R, Mahajan S, Bhagyaraj E, et al. The active form of vitamin D transcriptionally represses Smad7 signaling and activates extracellular signal-regulated kinase (ERK) to inhibit the differentiation of a inflammatory T helper cell subset and suppress experimental autoimmune encephalomyelitis. J Biol Chem. 2015;290:12222–12236.
   PubMed Web of Science ®Google Scholar
• Jeffery LE, Qureshi OS, Gardner D, et al. Vitamin D antagonises the suppressive effect of inflammatory cytokines on CTLA-4 expression and regulatory function. PLoS One. 2015;10:e0131539.
   PubMed Web of Science ®Google Scholar
• Bendix M, Dige A, Deleuran B, et al. Flow cytometry detection of vitamin D receptor changes during vitamin D treatment in Crohn's disease. Clin Exp Immunol. 2015;181:19–28.
   PubMed Web of Science ®Google Scholar
• Bendix M, Greisen S, Dige A, et al. Vitamin D increases programmed death receptor-1 expression in Crohn's disease. Oncotarget. 2017;8:24177–24186.
   PubMedGoogle Scholar
• McIlroy J, Ianiro G, Mukhopadhya I, et al. Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management. Aliment Pharmacol Ther. 2018;47:26–42.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet. 1991;338:771–774.
   PubMed Web of Science ®Google Scholar
• Shanahan F, Dinan TG, Ross P, et al. Probiotics in transition. Clin Gastroenterol Hepatol. 2012;10:1220–1224.
   PubMed Web of Science ®Google Scholar
• Christensen HR, Larsen CN, Kaestel P, et al. Immunomodulating potential of supplementation with probiotics: a dose-response study in healthy young adults. FEMS Immunol Med Microbiol. 2006;47:380–390.
   PubMed Web of Science ®Google Scholar
• Sheil B, McCarthy J, O'Mahony L, et al. Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Gut. 2004;53:694–700.
   PubMed Web of Science ®Google Scholar
• Mondel M, Schroeder BO, Zimmermann K, et al. Probiotic E. coli treatment mediates antimicrobial human beta-defensin synthesis and fecal excretion in humans. Mucosal Immunol. 2009;2:166–172.
   PubMed Web of Science ®Google Scholar
• Seo EJ, Weibel S, Wehkamp J, et al. Construction of recombinant E. coli Nissle 1917 (EcN) strains for the expression and secretion of defensins. Int J Med Microbiol. 2012;302:276–287.
   PubMed Web of Science ®Google Scholar
• Schlee M, Harder J, Koten B, et al. Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2. Clin Exp Immunol. 2008;151:528–535.
   PubMed Web of Science ®Google Scholar
• Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53:1617–1623.
   PubMed Web of Science ®Google Scholar
• Kruis W, Kiudelis G, Racz I, et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut. 2009;58:233–240.
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:305–309.
   PubMed Web of Science ®Google Scholar
• Ghouri YA, Richards DM, Rahimi EF, et al. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol. 2014;7:473–487.
   PubMedGoogle Scholar
• Naidoo K, Gordon M, Fagbemi AO, et al. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2011;Cd007443.
   PubMed Web of Science ®Google Scholar
• Butterworth AD, Thomas AG, Akobeng AK. Probiotics for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2008;Cd006634.
   PubMed Web of Science ®Google Scholar
• Rolfe VE, Fortun PJ, Hawkey CJ, et al. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2006;Cd004826.
   PubMed Web of Science ®Google Scholar
• O'Toole PW, Marchesi JR, Hill C. Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. Nat Microbiol. 2017;2:17057.
   PubMed Web of Science ®Google Scholar
• Kelly CR, Kahn S, Kashyap P, et al. Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology. 2015;149:223–237.
   PubMed Web of Science ®Google Scholar
• Eiseman B, Silen W, Bascom GS, et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958;44:854–859.
   PubMed Web of Science ®Google Scholar
• van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407–415.
   PubMed Web of Science ®Google Scholar
• Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107:1079–1087.
   PubMed Web of Science ®Google Scholar
• Mattila E, Uusitalo-Seppala R, Wuorela M, et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology. 2012;142:490–496.
   PubMed Web of Science ®Google Scholar
• Hamilton MJ, Weingarden AR, Sadowsky MJ, et al. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107:761–767.
   PubMed Web of Science ®Google Scholar
• Rubin TA, Gessert CE, Aas J, et al. Fecal microbiome transplantation for recurrent Clostridium difficile infection: report on a case series. Anaerobe. 2013;19:22–26.
   PubMed Web of Science ®Google Scholar
• Jiang ZD, Ajami NJ, Petrosino JF, et al. Randomised clinical trial: faecal microbiota transplantation for recurrent Clostridium difficile infection – fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy. Aliment Pharmacol Ther. 2017;45:899–908.
   PubMed Web of Science ®Google Scholar
• Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;41:835–843.
   PubMed Web of Science ®Google Scholar
• Kelly CR, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection. Ann Intern Med. 2016;165:609–616.
   PubMed Web of Science ®Google Scholar
• Hota SS, Sales V, Tomlinson G, et al. Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent Clostridium difficile infection: an open-label, randomized controlled trial. Clinid. 2017;64:265–271.
   Google Scholar
• Lee CH, Steiner T, Petrof EO, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2016;315:142–149.
   PubMed Web of Science ®Google Scholar
• Staley C, Hamilton MJ, Vaughn BP, et al. Successful resolution of recurrent Clostridium difficile infection using freeze-dried, encapsulated fecal microbiota; pragmatic cohort study. Am J Gastroenterol. 2017;112:940–947.
   PubMed Web of Science ®Google Scholar
• Kao D, Roach B, Silva M, et al. Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection. A randomized clinical trial. JAMA. 2017;318:1985–1993.
   PubMed Web of Science ®Google Scholar
• Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66:569–580.
   PubMed Web of Science ®Google Scholar
• Costello SP, Tucker EC, La Brooy J, et al. Establishing a fecal microbiota transplant service for the treatment of Clostridium difficile infection. Clin Infect Dis. 2016;62:908–914.
   PubMed Web of Science ®Google Scholar
• Jorgensen SMD, Hansen MM, Erikstrup C, et al. Faecal microbiota transplantation: establishment of a clinical application framework. Eur J Gastroenterol Hepatol. 2017;29:e36–e45.
   PubMed Web of Science ®Google Scholar
• Chin SM, Sauk J, Mahabamunuge J, et al. Fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease: a single-center experience. Clin Gastroenterol Hepatol. 2017;15:597–599.
   PubMed Web of Science ®Google Scholar
• Meighani A, Hart BR, Bourgi K, et al. Outcomes of fecal microbiota transplantation for Clostridium difficile infection in patients with inflammatory bowel disease. Dig Dis Sci. 2017;62:2870–2875.
   PubMed Web of Science ®Google Scholar
• Oppfeldt AM, Dahlerup JF, Christensen LA, et al. Faecal microbiota transplantation for recurring Clostridium difficile infection in a patient with Crohn's disease and ileorectal anastomosis. BMJ Case Rep. 2016. doi:10.1136/bcr-2016-217209
   PubMedGoogle Scholar
• Khoruts A, Rank KM, Newman KM, et al. Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol. 2016;14:1433–1438.
   PubMed Web of Science ®Google Scholar
• De Leon LM, Watson JB, Kelly CR. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol. 2013;11:1036–1038.
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149:102–109.e106.
   PubMed Web of Science ®Google Scholar
• Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015;149:110–118.e114.
   PubMed Web of Science ®Google Scholar
• Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389:1218–1228.
   PubMed Web of Science ®Google Scholar
• Kump P, Wurm P, Grochenig HP, et al. The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis. Aliment Pharmacol Ther. 2018;47:67–77.
   PubMed Web of Science ®Google Scholar
• Paramsothy S, Paramsothy R, Rubin DT, et al. Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2017;11:1180–1199.
   PubMed Web of Science ®Google Scholar
• Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2014;8:1569–1581.
   PubMed Web of Science ®Google Scholar
• Khoruts A, Sadowsky MJ. Understanding the mechanisms of faecal microbiota transplantation. Nat Rev Gastroenterol Hepatol. 2016;13:508–516.
   PubMed Web of Science ®Google Scholar
• Hourigan SK, Chen LA, Grigoryan Z, et al. Microbiome changes associated with sustained eradication of Clostridium difficile after single faecal microbiota transplantation in children with and without inflammatory bowel disease. Aliment Pharmacol Ther. 2015;42:741–752.
   PubMed Web of Science ®Google Scholar
• Khanna S, Vazquez-Baeza Y, Gonzalez A, et al. Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying inflammatory bowel disease. Microbiome. 2017;5:55.
   PubMed Web of Science ®Google Scholar
• Weingarden AR, Chen C, Bobr A, et al. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol. 2014;306:G310–G319.
   PubMed Web of Science ®Google Scholar
• Ott SJ, Waetzig GH, Rehman A, et al. Efficacy of sterile fecal filtrate transfer for treating patients with Clostridium difficile infection. Gastroenterology. 2017;152:799–811.e797.
   PubMed Web of Science ®Google Scholar
• Carding SR, Davis N, Hoyles L. Review article: the human intestinal virome in health and disease. Aliment Pharmacol Ther. 2017;46:800–815.
   PubMed Web of Science ®Google Scholar
• Elliott DE, Summers RW, Weinstock JV. Helminths and the modulation of mucosal inflammation. Curr Opin Gastroenterol. 2005;21:51–58.
   PubMed Web of Science ®Google Scholar
• Summers RW, Elliott DE, Qadir K, et al. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2003;98:2034–2041.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Elliott DE, Weinstock J, et al. Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease. Aliment Pharmacol Ther. 2013;38:255–263.
   PubMed Web of Science ®Google Scholar
• Dige A, Rasmussen TK, Nejsum P, et al. Mucosal and systemic immune modulation by Trichuris trichiura in a self-infected individual. Parasite Immunol. 2017;39:12394.
   Web of Science ®Google Scholar
• Williams AR, Dige A, Rasmussen TK, et al. Immune responses and parasitological observations induced during probiotic treatment with medicinal Trichuris suis ova in a healthy volunteer. Immunol Lett. 2017;188:32–37.
   PubMed Web of Science ®Google Scholar
• Summers RW, Elliott DE, Urban JF Jr, et al. Trichuris suis therapy in Crohn's disease. Gut. 2005;54:87–90.
   PubMed Web of Science ®Google Scholar
• Summers RW, Elliott DE, Urban JF Jr, et al. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology. 2005;128:825–832.
   PubMed Web of Science ®Google Scholar
• Scholmerich J, Fellermann K, Seibold FW, et al. A randomised, double-blind, placebo-controlled trial of Trichuris suis ova in active Crohn's disease. J Crohns Colitis. 2017;11:390–399.
   PubMed Web of Science ®Google Scholar
• Vagianos K, Clara I, Carr R, et al. What are adults with inflammatory bowel disease (IBD) eating? A closer look at the dietary habits of a population-based Canadian IBD cohort. JPEN J Parenter Enteral Nutr. 2016;40:405–411.
   PubMed Web of Science ®Google Scholar
• Lee D, Albenberg L, Compher C, et al. Diet in the pathogenesis and treatment of inflammatory bowel diseases. Gastroenterology. 2015;148:1087–1106.
   PubMed Web of Science ®Google Scholar
• Valentini L, Schaper L, Buning C, et al. Malnutrition and impaired muscle strength in patients with Crohn's disease and ulcerative colitis in remission. Nutrition. 2008;24:694–702.
   PubMed Web of Science ®Google Scholar
• Geerling BJ, Badart-Smook A, Stockbrugger RW, et al. Comprehensive nutritional status in patients with long-standing Crohn disease currently in remission. Am J Clin Nutr. 1998;67:919–926.
   PubMed Web of Science ®Google Scholar
• Nguyen GC, Munsell M, Harris ML. Nationwide prevalence and prognostic significance of clinically diagnosable protein-calorie malnutrition in hospitalized inflammatory bowel disease patients. Inflamm Bowel Dis. 2008;14:1105–1111.
   PubMed Web of Science ®Google Scholar
• Conlon MA, Bird AR. The impact of diet and lifestyle on gut microbiota and human health. Nutrients. 2014;7:17–44.
   PubMed Web of Science ®Google Scholar
• Parian AM, Limketkai BN, Shah ND, et al. Nutraceutical supplements for inflammatory bowel disease. Nutr Clin Pract. 2015;30:551–558.
   PubMed Web of Science ®Google Scholar
• Halmos EP, Gibson PR. Dietary management of IBD-insights and advice. Nat Rev Gastroenterol Hepatol. 2015;12:133–146.
   PubMed Web of Science ®Google Scholar
• Lewis JD, Abreu MT. Diet as a trigger or therapy for inflammatory bowel diseases. Gastroenterology. 2017;152:398–414.e396.
   PubMed Web of Science ®Google Scholar
• Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995;125:1401–1412.
   PubMed Web of Science ®Google Scholar
• Riviere A, Selak M, Lantin D, et al. Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut. Front Microbiol. 2016;7:979.
   PubMed Web of Science ®Google Scholar
• Wedlake L, Slack N, Andreyev HJ, et al. Fiber in the treatment and maintenance of inflammatory bowel disease: a systematic review of randomized controlled trials. Inflamm Bowel Dis. 2014;20:576–586.
   PubMed Web of Science ®Google Scholar
• Brotherton CS, Martin CA, Long MD, et al. Avoidance of fiber is associated with greater risk of Crohn's disease flare in a 6-month period. Clin Gastroenterol Hepatol. 2016;14:1130–1136.
   PubMed Web of Science ®Google Scholar
• Karner M, Kocjan A, Stein J, et al. First multicenter study of modified release phosphatidylcholine "LT-02" in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses. Am J Gastroenterol. 2014;109:1041–1051.
   PubMed Web of Science ®Google Scholar
• Hvas CL, Dige A, Bendix M, et al. Casein glycomacropeptide for active distal ulcerative colitis: a randomized pilot study. Eur J Clin Invest. 2016;46:555–563.
   PubMed Web of Science ®Google Scholar
• Bengmark S. Curcumin, an atoxic antioxidant and natural NFkappaB, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases. JPEN J Parenter Enteral Nutr. 2006;30:45–51.
   PubMed Web of Science ®Google Scholar
• Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4:1502–1506.
   PubMed Web of Science ®Google Scholar
• Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci. 2005;50:2191–2193.
   PubMed Web of Science ®Google Scholar
• Kumar S, Ahuja V, Sankar MJ, et al. Curcumin for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;10:Cd008424.
   PubMedGoogle Scholar
• Kedia S, Bhatia V, Thareja S, et al. Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: results from a randomized double blind placebo controlled trial. World J Gastrointest Pharmacol Ther. 2017;8:147–154.
   PubMedGoogle Scholar
• Lang A, Salomon N, Wu JC, et al. Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial. Clin Gastroenterol Hepatol. 2015;13:1444–1449.e1441.
   PubMed Web of Science ®Google Scholar
• Holt PR. Curcumin for inflammatory bowel disease: a caution. Clin Gastroenterol Hepatol. 2016;14:168.
   PubMed Web of Science ®Google Scholar
• Marks PW, Witten CM, Califf RM. Clarifying stem-cell therapy's benefits and risks. N Engl J Med. 2017;376:1007–1009.
   PubMed Web of Science ®Google Scholar
• Panes J, Rimola J. Perianal fistulizing Crohn's disease: pathogenesis, diagnosis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14:652–664.
   PubMed Web of Science ®Google Scholar
• Panes J, Garcia-Olmo D, Van Assche G, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388:1281–1290.
   PubMed Web of Science ®Google Scholar
• Dietz AB, Dozois EJ, Fletcher JG, et al. Autologous mesenchymal stem cells, applied in a bioabsorbable matrix, for treatment of perianal fistulas in patients with Crohn's disease. Gastroenterology. 2017;153:59–62.e2.
   PubMed Web of Science ®Google Scholar
• Cryan JF, O'Mahony SM. The microbiome–gut–brain axis: from bowel to behavior. Neurogastroenterol Motil. 2011;23:187–192.
   PubMed Web of Science ®Google Scholar
• De Palma G, Collins SM, Bercik P, et al. The microbiota–gut–brain axis in gastrointestinal disorders: stressed bugs, stressed brain or both? J Physiol. 2014;592:2989–2997.
   PubMed Web of Science ®Google Scholar
• Rasmussen SE, Pfeiffer-Jensen M, Drewes AM, et al. Vagal influences in rheumatoid arthritis. Scand J Rheumatol. 2017;47:1–11.
   PubMed Web of Science ®Google Scholar
• Koopman FA, Chavan SS, Miljko S, et al. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proc Natl Acad Sci USA. 2016;113:8284–8289.
   PubMed Web of Science ®Google Scholar
• Bonaz B, Sinniger V, Hoffmann D, et al. Chronic vagus nerve stimulation in Crohn's disease: a 6-month follow-up pilot study. Neurogastroenterol Motil. 2016;28:948–953.
   PubMed Web of Science ®Google Scholar
• Bregeon J, Coron E, Da Silva AC, et al. Sacral nerve stimulation enhances early intestinal mucosal repair following mucosal injury in a pig model. J Physiol. 2016;594:4309–4323.
   PubMed Web of Science ®Google Scholar
• Jarrett ME, Mowatt G, Glazener CM, et al. Systematic review of sacral nerve stimulation for faecal incontinence and constipation. Br J Surg. 2004;91:1559–1569.
   PubMed Web of Science ®Google Scholar
• Bregeon J, Neunlist M, Bossard C, et al. Improvement of refractory ulcerative proctitis with sacral nerve stimulation. J Clin Gastroenterol. 2015;49:853–857.
   PubMed Web of Science ®Google Scholar